ER/PR-positive breast cancer with separate solitary rib plasmacytoma: disease-free after breast and plasmacytoma treatment

Patient Info: Anonymized, Female, 60s

Biomarkers: Breast cancer: ER-positive, PR-positive, HER2-negative

More than 5 years after treatment, she remained disease-free with no recurrence of either ER/PR-positive breast cancer or the separate solitary rib plasmacytoma.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement responding to T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement treated with T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Courtney's Patient Story

Patient Info: Courtney, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

As of June 2025, Courtney was recovering from Stage III ER-positive, PR-positive, HER2-negative ILC treatment after double mastectomy, Taxotere/Cytoxan chemotherapy, and 25 rounds of radiation, with reconstructive surgery delayed by radiation skin injury.

Lobular Breast Cancer AllianceRead more →

HR-Positive Breast Cancer: Sara's Patient Story

Patient Info: Sara Glenn, Female, Under 40

Biomarkers: TP53 mutation / Li-Fraumeni syndrome; ER-positive; HER2-negative

As of June 2025, Sara had completed bilateral mastectomy and reconstruction for ER-positive, HER2-negative breast cancer and was on planned 10-year tamoxifen plus intensive Li-Fraumeni syndrome surveillance for herself and her daughters.

City of HopeRead more →

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-FarberRead more →

Breast cancer history: T9 osteonecrosis mimicking spinal metastasis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER status not explicitly reported; prior tamoxifen use reported

As of June 2025, the T9 lesion that had raised concern for spinal metastasis was confirmed as osteonecrosis, and eight-month follow-up showed no evidence of recurrence or new pain episodes.

PubMed CentralRead more →

Metastatic male breast cancer: complete metabolic response after restarting anastrozole, leuprolide, abemaciclib, zoledronic acid, and radiation

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER >95%; PR >95%; HER2/neu-negative; Ki-67 30%; PIK3CA exon 21 pathogenic variant; BRCA1 not mutated; BRCA2 not mutated

Metastatic Site: bone (vertebral bodies T2-T6, L1, and L5)

As of May 2025, after restarting endocrine and targeted therapy and receiving palliative radiation, the last two PET scans showed complete metabolic response without disease progression, and brain MRI showed no metastasis.

PubMed CentralRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 1

As of May 2025, Tanya was recovering from chest wall surgery, ALT flap repair, and a later skin graft after developing angiosarcoma in her radiated reconstructed breast years after Stage IIIA ILC treatment.

Lobular Breast Cancer AllianceRead more →

Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed CentralRead more →

Breast Cancer: Honey's Survivor Story

Patient Info: Honey, Female

Honey completed surgical treatment for breast cancer with clear lymph nodes and margins. She declined radiation and chemotherapy, later stopped tamoxifen, and focused on recovery from surgical menopause symptoms and returning to art. No recurrence or metastatic disease was described.

The Patient StoryRead more →

Stage IIIB ER/PR-positive breast cancer: emergency mastectomy for infected fungating tumor

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER >75%; PR >75%; HER2 0 / HER2-negative; grade 3 invasive ductal carcinoma

As of May 2025, management centered on anastrozole after emergency mastectomy, repeated debridements, wound care, and major postoperative complications; oncology follow-up had become inconsistent because of ongoing medical setbacks.

PubMed CentralRead more →

Stage I Breast Cancer: Krista's Patient Story

Patient Info: Krista, Female | Stage I

Biomarkers: ATM mutation; hormone receptor-positive; HER2-negative; Oncotype DX score 1

As of May 2025, Krista had undergone double mastectomy with flap reconstruction for Stage IA hormone receptor-positive, HER2-negative breast cancer and was taking tamoxifen with minimal early side effects.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40 | Stage II

Biomarkers: ER-positive; comprehensive genetic panel negative

As of May 2025, LaShae had completed mastectomy for Stage IIB ER-positive breast cancer with 2 positive lymph nodes and was undergoing chemotherapy, with radiation and 5-10 years of hormone therapy planned.

The Patient StoryRead more →

Early-stage triple-negative breast cancer with separate lung carcinoid and later CML

Patient Info: Anonymized, Female, 50s

Biomarkers: triple negative

As of May 2025, serial follow-up breast ultrasound examinations showed no evidence of breast cancer recurrence in either breast tissue or axillary lymph nodes.

PubMed CentralRead more →

Stage IA ER/PR-positive breast cancer in SLE: arm-behind-back radiation after lumpectomy

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER >95%; PR >95%; HER2 1+; Ki-67 23%; no BRCA1/2 variants identified

As of April 2025, 15 months after 3D conformal radiotherapy, she had no local recurrence, no distant metastasis, and no radiation pneumonitis.

PubMed CentralRead more →

Primary neuroendocrine breast tumor: disease-free 5 years after mastectomy and tamoxifen

Patient Info: Anonymized, Female, 50s

Biomarkers: Neuroendocrine breast tumor: ER/PR positive, HER2 negative

As of April 2025, she had remained disease-free for 5 years after mastectomy, negative sentinel lymph node biopsy, and tamoxifen 20 mg once daily.

PubMed CentralRead more →

Stage IIA ER-positive breast cancer with axillary tuberculosis: no metabolically active disease after treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER 78% positive; PR-negative; HER2/neu-negative; Ki-67 21%; Luminal A subtype

As of April 2025, follow-up PET-CT showed no metabolically active disease after mastectomy, adjuvant anthracycline-based chemotherapy, letrozole, and 6 months of anti-tuberculosis therapy.

PubMed CentralRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Mandy's Patient Story

Patient Info: Mandy, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; low Oncotype score; genetic testing negative for 70 cancer-causing genes

As of April 2025, Mandy was about 10 months after bilateral mastectomy for Stage IA ER-positive, PR-positive ILC, had a low Oncotype score, was planning several years of tamoxifen, and was still in reconstruction.

Lobular Breast Cancer AllianceRead more →

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed CentralRead more →

Right Stage IIB ER/PR-positive breast cancer with left epithelioid MPNST: no recurrence after surgery

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Right breast cancer was ER/PR-positive, HER2-negative/1+

As of March 2025, 3 years after bilateral mastectomy, there was no recurrence of the right breast cancer or the left epithelioid malignant peripheral nerve sheath tumor; she remained on anastrozole for the right breast cancer.

PubMed CentralRead more →

Left breast epithelioid MPNST with concurrent right breast cancer: no recurrence after surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Left MPNST markers included S100 and SOX10 positivity. Right breast cancer was ER/PR-positive, HER2-negative/1+

As of March 2025, 3 years after bilateral mastectomy, there was no recurrence of the left epithelioid MPNST or the concurrent right breast invasive ductal carcinoma.

PubMed CentralRead more →